Zhichao Tong

Dr. Zhichao Tong


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FKFlorian Gerhard Klein
Florian Gerhard Klein
CGCharlene Granier
Charlene Granier
YZYuling Zhao
Yuling Zhao
QPQi Pan
Qi Pan
ZTZhichao Tong
Zhichao Tong
Roman NawrothRoman Nawroth
Roman Nawroth
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen.

5 June 2025 in Advanced Science
Verified
Journal Article
Open access
HSHongjian Song
Hongjian Song
ZTZhichao Tong
Zhichao Tong
GXGuixiang Xie
Guixiang Xie
YLYaowei Li
Yaowei Li
YZYubo Zhao
Yubo Zhao
WXwanhai xu
wanhai xu
Penile squamous cell carcinoma (PSCC) is a highly aggressive malignancy without effective treatment due to limited knowledge of its development and tumor microenvironment (TME). In this study, single‐nucleus RNA sequencing (snRNA‐seq) and high‐resolution spatial transcriptomics are employed to comprehensively investigate the development trajectories and the TME. The results revealed that PSCC cells mimicked the differentiation and tissue organization of normal penile epithelium, independent of the human papillomavirus (HPV) infection status. Notably, a spatial subtype, Tum_1, appeared at early stage of tumor differentiation and in tumor–normal boundary regions. This subtype exhibited enhanced basal‐like and stemness features and showed high LAMC2 expression, which activated laminin‐integrin signaling via ITGA6/ITGB4, promoting tumor invasiveness. Furthermore, the results indicated that HPV‐positive basal stem‐like neoplasms dampened the immune function of T cells and macrophages, promoting an immunosuppressive environment that facilitates tumor progression. Supporting this, the patients with head and neck squamous cell carcinoma and lung squamous cell carcinoma who have high expression of HPV‐positive Tum_1 signatures derived greater benefit from PD‐1 blockade therapy. In summary, the findings provide a comprehensive spatial landscape of the PSCC TME and suggest potential treatment approaches targeting laminin‐integrin interaction and immunotherapy, especially in HPV‐positive patients.

9 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HSHongjian Song
Hongjian Song
GXGuixiang Xie
Guixiang Xie
YLYaowei Li
Yaowei Li
XHXiaowei Hu
Xiaowei Hu
ZYZongzheng Yang
Zongzheng Yang
WXwanhai xu
wanhai xu
Purpose Bladder cancer (BC) is characterized by high heterogeneity, with non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) stages differing significantly in clinical behavior and outcomes. The transition from NMIBC to MIBC involves extensive tumor microenvironment (TME) remodeling, particularly in endothelial cells (ECs), which drive angiogenesis and modulate immune and extracellular matrix (ECM) interactions. However, the precise roles of ECs in this progression remain poorly defined. Methods Public single-cell RNA sequencing (scRNA-seq) datasets from 47 BC patients were analyzed to characterize endothelial cell heterogeneity and functional states across NMIBC and MIBC. Computational tools such as CellChat were applied to reconstruct cell–cell communication networks, focusing on pathways related to angiogenesis, immune crosstalk, and ECM remodeling. Results Twelve major cell types were identified, with endothelial cells exhibiting distinct transcriptional profiles between NMIBC and MIBC. NMIBC-associated ECs promoted adhesion and migration through HMGB1 and CXCL12 signaling. In contrast, MIBC was enriched in an ADAM10+ endothelial subset associated with vascular remodeling and activation of Wnt signaling via CTNNB1. Key ligand-receptor interactions highlighted the dynamic roles of ECs in TME modulation during BC progression. Conclusions This study reveals stage-specific endothelial cell phenotypes and signaling networks in BC. The identification of an MIBC-specific ADAM10+ endothelial subset underscores its potential role in driving tumor progression and highlights opportunities for stage-adapted vascular-targeted therapies. These findings advance our understanding of BC pathogenesis and provide the foundation for novel therapeutic strategies.

1 January 2026 in Oncology Research
Verified
Journal Article
Open access
PDF file
ZYZhihao Yin
Zhihao Yin
XZXi Zhen
Xi Zhen
HLHaonan Li
Haonan Li
HDHaiqiang Duan
Haiqiang Duan
XHXiaowei Hu
Xiaowei Hu
ZTZhichao Tong
Zhichao Tong
Backgrounds: Tertiary lymphoid structures (TLSs) are increasingly recognized as modulators of anti-tumor immunity, yet their clinical relevance in bladder cancer remains incompletely understood, partly owing to heterogeneity in their maturation states. Here, we demonstrate that germinal center (GC)–like TLS maturity, rather than TLS presence alone, is closely associated with immune activation and therapeutic response to Programmed Death-Ligand 1 (PD-L1) blockade in bladder cancer. The objective of this study was to systematically investigate the clinical significance, biological function, and therapeutic potential of tertiary lymphoid structure (TLS) maturation in bladder cancer. Specifically, we aimed to determine whether GC-like TLS maturity provides prognostic and predictive value beyond TLS presence alone, to elucidate the immune programs and tumor microenvironment remodeling associated with TLS maturation, and to explore whether TLS maturation can be therapeutically induced to enhance responsiveness to PD-L1 blockade. Methods: We performed an integrative analysis combining multi-cohort transcriptomics, spatially resolved histopathology, single-cell RNA sequencing, and functional murine experiments. TLS maturation states were defined using gene-expression–based GC-like TLS signatures and validated through multiplex immunohistochemistry. Clinical relevance was assessed in public immunotherapy cohorts and an independent neoadjuvant PD-L1–treated muscle-invasive bladder cancer (MIBC) cohort. Tumor immune microenvironment remodeling and chemokine-mediated cellular crosstalk were analyzed using deconvolution, Weighted Gene Co-expression Network Analysis (WGCNA), and CellChat. The therapeutic inducibility of TLS maturation was examined using a lymphotoxin-β receptor (LTβR) agonist in combination with PD-L1 blockade in a syngeneic bladder cancer model. Results: Across multiple transcriptomic cohorts, tumors enriched for GC-like TLS signatures exhibited significantly prolonged survival and higher objective response rates to anti–PD-L1 therapy, whereas less mature TLS phenotypes showed no consistent association with clinical association. These observations were independently validated in a neoadjuvant PD-L1–treated muscle-invasive bladder cancer cohort, in which high mature TLS density was associated with major pathological response and prolonged event-free survival, outperforming PD-L1 expression. Integrative histopathological and transcriptomic analyses indicated that GC formation marks a functional transition linking humoral immune programs with cytotoxic effector activity and shaping a memory-prone, pro-inflammatory tumor immune microenvironment. Chemokine signaling via the CC chemokine ligand 21 (CCL21)–C-C chemokine receptor type 7 (CCR7) and C-X-C motif chemokine ligand 12 (CXCL12)–C-X-C chemokine receptor type 4 (CXCR4) axes was strongly associated with TLS maturation and spatial organization. Finally, in a syngeneic bladder cancer model, pharmacological activation of lymphotoxin-β receptor signaling promoted TLS maturation and enhanced the antitumor efficacy of PD-L1 blockade. Conclusions: Together, these findings suggest that GC-like TLS maturity represents a clinically relevant biomarker and a potential therapeutic entry point for precision immunotherapy in bladder cancer. Therapeutic strategies that promote TLS maturation may convert immune-cold tumors into checkpoint-responsive states, providing a mechanistically grounded precision immunotherapy approach.

6 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
QPQi Pan
Qi Pan
QSQing Shi
Qing Shi
YZYubo Zhao
Yubo Zhao
TYTianxi Yu
Tianxi Yu
SBShiyu Bai
Shiyu Bai
ZTZhichao Tong
Zhichao Tong
Background: CDK4/6 inhibitors induce G1/S cell-cycle arrest in bladder cancer; however, adaptive resistance limits their therapeutic efficacy. The role of the m6A reader IGF2BP3 in regulating sensitivity to CDK4/6 inhibition remains largely unknown. Methods: Transcriptomic profiling was performed in palbociclib-treated bladder cancer cell lines (T24, RT112, and UMUC-3) to identify m6A regulators associated with drug response. The expression and clinical significance of IGF2BP3 were evaluated using The Cancer Genome Atlas (TCGA) data and an independent clinical cohort. Gain- and loss-of-function assays were conducted to investigate the effects of IGF2BP3 on cell proliferation and cell-cycle progression. Mechanistic studies, including RNA-binding, mRNA stability, ubiquitination, and in vivo tumorigenesis assays, were performed to elucidate the underlying regulatory network. Results: IGF2BP3 was identified as the only m6A regulator differentially expressed following palbociclib treatment. IGF2BP3 expression was significantly elevated in bladder cancer tissues compared with normal tissues and was associated with poor prognosis and Ki67 positivity. Functionally, IGF2BP3 overexpression (OE) promoted G1/S transition, increased MYC and downstream cell-cycle regulators, and partially rescued palbociclib-induced cell-cycle arrest, whereas IGF2BP3 knockdown (KD) suppressed cell proliferation in an MYC-dependent manner. Mechanistically, IGF2BP3 bound to MYC mRNA in an m6A-dependent manner and enhanced its stability. Furthermore, MKRN2 was identified as an E3 ubiquitin ligase that directly interacted with IGF2BP3, promoted its ubiquitination, and facilitated its proteasomal degradation. In vivo, MKRN2 co-overexpression attenuated IGF2BP3-driven tumor growth and synergized with palbociclib to maximally suppress tumor volume, reduce MYC and Ki67 expression, and induce apoptosis. Conclusions: These findings establish the MKRN2–IGF2BP3–MYC axis as a critical regulator of CDK4/6 inhibitor sensitivity in bladder cancer. Targeting IGF2BP3 or enhancing MKRN2 activity may represent a promising strategy to overcome adaptive resistance and improve the therapeutic efficacy of CDK4/6 inhibitors.

13 June 2026 in Discover Oncology
Verified
Journal Article
Open access
XHXiaowei Hu
Xiaowei Hu
ZYZongzheng Yang
Zongzheng Yang
QSQing Shi
Qing Shi
TYTianxi Yu
Tianxi Yu
YLYaowei Li
Yaowei Li
YZYubo Zhao
Yubo Zhao
Bladder cancer progression and chemoresistance remain major clinical challenges, yet the molecular determinants underlying these aggressive phenotypes are incompletely understood. Integrating TCGA transcriptomics, GEO single-cell transcriptomics, patient tissue profiling, flow cytometry-based cell sorting, functional perturbation assays, and xenograft models, we investigated the cooperative roles of NEK2, ZWINT, and the downstream effector NDC80 in bladder cancer biology. We identified a previously unrecognized NEK2/ZWINT-NDC80 regulatory axis that governs malignant cell behavior. NEK2 and ZWINT were markedly co-upregulated in high-grade tumors and strongly associated with EMT-related transcriptional programs. NEK2⁺ZWINT⁺ double-positive cells represented a stable and aggressive tumor subpopulation enriched in invasive lesions. Dual knockdown of NEK2 and ZWINT profoundly impaired proliferation, clonogenicity, motility, and in vivo tumorigenicity, whereas single-gene perturbation produced only partial effects. Mechanistically, NDC80 acted as a critical downstream effector, integrating NEK2-ZWINT signals and acting as a key downstream effector that integrates signals from NEK2 and ZWINT to drive malignant phenotypes. NDC80 depletion suppressed tumor growth and significantly increased gemcitabine sensitivity. Clinically, NDC80 expression correlated with advanced stage and chemoresistant bladder cancer tissues. Our findings reveal the NEK2-ZWINT-NDC80 axis as a central regulatory module driving bladder cancer progression and gemcitabine resistance. Targeting this axis may offer a therapeutic strategy for high-risk bladder cancer.